Anti-Fungal Drugs Market 2020 By Industry Size Estimation, Industry Share, Future Demand, Dynamics, Drivers

The global anti-fungal drugs market size is likely to reach USD 13.17 billion by 2027 on account of the increasing prevalence of skin infections worldwide. Mycosis or fungal infection is a skin disease caused by a group of spore-producing organisms living and feeding on the human skin. When untreated, they lead to skin issues such as rashes, athlete’s foot, yeast infection, ringworm, nail fungus, bumps, and others. According to a recently published report by Fortune Business Insights™ titled, “Anti-Fungal Drugs Market Size, Share & Industry Analysis, By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Others), and Regional Forecast, 2020-2027,” the market value was USD 10.24 billion in 2019, and will exhibit a CAGR of 3.3% between 2020 and 2027.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antifungal-drugs-market-101188

Key Players Operating in The Anti-Fungal Drugs Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Merck & Co., Inc.
• Leadiant Biosciences, Inc.
• GlaxoSmithKline plc.
• Bayer AG
• Astellas Pharma Inc.
• Pfizer Inc.
• McKesson Medical-Surgical Inc.
• Novartis AG
• Abbott
• Other Players

Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/antifungal-drugs-market-101188

Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
4.2. Prevalence of Fungal Infections
4.3. Pipeline Analysis
4.4. New Product Launches
5. Global Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Type
5.2.1. Azoles
5.2.2. Echinocandins
5.2.3. Polyenes
5.2.4. Allylamines
5.3. Market Analysis, Insights and Forecast – By Indication
5.3.1. Dermatophytosis
5.3.2. Candidiasis
5.3.3. Aspergillosis
5.3.4. Others
5.4. Market Analysis, Insights and Forecast – By Route of Administration
5.4.1. Oral
5.4.2. Topical
5.4.3. Parenteral
5.5. Market Analysis, Insights and Forecast – By Distribution Channel
5.5.1. Hospitals Pharmacies
5.5.2. Retail Pharmacies & Drug Stores
5.5.3. Online Pharmacies
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Type
6.2.1. Azoles
6.2.2. Echinocandins
6.2.3. Polyenes
6.2.4. Allylamines
6.3. Market Analysis – By Indication
6.3.1. Dermatophytosis
6.3.2. Candidiasis
6.3.3. Aspergillosis
6.3.4. Others
6.4. Market Analysis – By Route of Administration
6.4.1. Oral
6.4.2. Topical
6.4.3. Parenteral
6.5. Market Analysis – By Distribution Channel
6.5.1. Hospitals Pharmacies
6.5.2. Retail Pharmacies & Drug Stores
6.5.3. Online Pharmacies
6.6. Market Analysis – By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Type
7.2.1. Azoles
7.2.2. Echinocandins
7.2.3. Polyenes
7.2.4. Allylamines
7.3. Market Analysis – By Indication
7.3.1. Dermatophytosis
7.3.2. Candidiasis
7.3.3. Aspergillosis
7.3.4. Others
7.4. Market Analysis – By Route of Administration
7.4.1. Oral
7.4.2. Topical
7.4.3. Parenteral
7.5. Market Analysis – By Distribution Channel
7.5.1. Hospitals Pharmacies
7.5.2. Retail Pharmacies & Drug Stores
7.5.3. Online Pharmacies
7.6. Market Analysis – By Country/ sub-region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Scandinavia
7.6.7. Rest of Europe
8. Asia pacific Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Type
8.2.1. Azoles
8.2.2. Echinocandins
8.2.3. Polyenes
8.2.4. Allylamines
8.3. Market Analysis – By Indication
8.3.1. Dermatophytosis
8.3.2. Candidiasis
8.3.3. Aspergillosis
8.3.4. Others
8.4. Market Analysis – By Route of Administration
8.4.1. Oral
8.4.2. Topical
8.4.3. Parenteral
8.5. Market Analysis – By Distribution Channel
8.5.1. Hospitals Pharmacies
8.5.2. Retail Pharmacies & Drug Stores
8.5.3. Online Pharmacies
8.6. Market Analysis – By Country/ sub-region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
9. Latin America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Type
9.2.1. Azoles
9.2.2. Echinocandins
9.2.3. Polyenes
9.2.4. Allylamines
9.3. Market Analysis – By Indication
9.3.1. Dermatophytosis
9.3.2. Candidiasis
9.3.3. Aspergillosis
9.3.4. Others
9.4. Market Analysis – By Route of Administration
9.4.1. Oral
9.4.2. Topical
9.4.3. Parenteral
9.5. Market Analysis – By Distribution Channel
9.5.1. Hospitals Pharmacies
9.5.2. Retail Pharmacies & Drug Stores
9.5.3. Online Pharmacies
9.6. Market Analysis – By Country/ sub-region
9.6.1. Brazil
9.6.2. Mexico
9.6.3. Rest of Latin America
10. Middle East & Africa Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Drug Type
10.2.1. Azoles
10.2.2. Echinocandins
10.2.3. Polyenes
10.2.4. Allylamines
10.3. Market Analysis – By Indication
10.3.1. Dermatophytosis
10.3.2. Candidiasis
10.3.3. Aspergillosis
10.3.4. Others
10.4. Market Analysis – By Route of Administration
10.4.1. Oral
10.4.2. Topical
10.4.3. Parenteral
10.5. Market Analysis – By Distribution Channel
10.5.1. Hospitals Pharmacies
10.5.2. Retail Pharmacies & Drug Stores
10.5.3. Online Pharmacies
10.6. Market Analysis – By Country/ sub-region
10.6.1. GCC Countries
10.6.2. South Africa
10.6.3. Rest of Middle East & Africa
Continued...

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.